CAS: 137-66-6; (S)-2-((R)-3,4-Dihydroxy-5-Oxo-2,5-Dihydrofuran-2-yl)-2-Hydroxyethyl Palmitate

相似化合物

50-81-7 89-65-6 10605-09-1

上下游产品

维生素 C Ascorbic Acid 50-81-7
5,6-O-Isopropylidene-L-Ascorbic Acid 15042-01-0
[(2S)-2-[(2R)-3,4-Dibenzyloxy-5-Oxo-2H-Furan-2-Yl]-2-Hydroxyethyl] Hexadecanoate 914771-19-0
(2R)-3,4-Dibenzyloxy-2-[(1S)-1,2-Dihydroxyethyl]-2H-Furan-5-One 99663-32-8
(R)-3,4-Bis(Benzyloxy)-5-((S)-2,2-Dimethyl-1,3-Dioxolan-4-yl)Furan-2(5H)-One 2871-84-3

维生素 C置于palladium On Activated Charcoal 吡啶,4-二甲氨基吡啶,氢气,Potassium Carbonate,溶剂黄146,乙酰氯体系中,用 甲醇,乙醇,二氯甲烷,N,N-二甲基甲酰胺 用作溶剂,80.0 °C,400.0 Kpa 条件下,反应生成L-抗坏血酸棕榈酸酯
参考文献:Novel 6-O-Acylated Vitamin C Derivatives As Hyaluronidase Inhibitors With Selectivity For Bacterial Lyases
标题:Novel 6-O-Acylated Vitamin C Derivatives As Hyaluronidase Inhibitors With Selectivity For Bacterial Lyases
摘要:Previously,We Identified Ascorbic Acid 6-O-Hexadecanoate As An Up To 1500 Times More Potent Inhibitor Of Bacterial And Bovine Hyaluronidases Than The Parent Compound,Vitamin C,And Determined A Crystal Structure Of Hyaluronidase From Streptococcus Pneumoniae In Complex With The Inhibitor. As The Alkanoyl Chain Interacts With A Hydrophobic Patch Of The Enzyme We Synthesized Other 6-O-Acylated Vitamin C Derivatives Bearing Various Lipophilic Residues And Investigated The Inhibition Of Streptococcus Agalactiae Strain 4755 Hyaluronidase (Saghyal(4755)) And Of Bovine Testicular Hyaluronidases (Bth) In A Turbidimetric Assay. All Compounds Showed Selectivity For The Bacterial Enzyme. Whereas Vitamin C 6-O-Hexanoate Only Weakly Inhibited Saghyal(4755),The Inhibition Of Both Enzymes Increased With The Length Of The Aliphatic Chain. In The Case Of The 6-O-octadecanoate,Ic50 Values Of 0.9 And 39 Mu M For Saghyal(4755) And Bth,Respectively,Were Determined. Partial Replacement Of The Aliphatic Chain With A Phenyl,P-Phenylene Or P-Biphenylyl Group Resulted In Inhibitors With Activity In The Lower Micromolar Range,Too. The Title Compounds Are Among The Most Potent Inhibitors Of Both Enzymes Known To Date. (C) 2006 Elsevier Ltd. All Rights Reserved.
Doi:10.1016/j.Bmcl.2006.07.087

专利信息

专利号:US-7230101-B1
优先权日:2002-08-28
标 题:Synthesis of methotrexate-containing heterodimeric molecules
发明人：MURTHI KRISHNA K; SMITH CHASE C
权利人:GPC BIOTECH INC
摘要:The present invention relates to novel compositions of methotrexate-containing heterodimeric probe molecules, also known as chemical inducers of dimerization (CID), useful in three-hybrid assays. The invention further relates to synthesis of said compositions and their intermediates. Another aspect of the invention is a method for using the heterodimeric probe molecules described herein in drug screens to identify potential protein targets to a given ligand, optimize protein-ligand interactions, or identify potential ligands for a given protein target. In certain embodiments, the invention contemplates the synthesis of the following methotrexate-containing heterodimeric probe:

专利号:US-6579725-B1
优先权日:1999-03-05
标题 :Linkers for synthesis of oligosaccharides on solid supports
发明人：SEEBERGER PETER H; ANDRADE RODRIGO B
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:The present invention relates to versatile linkers for tethering a molecule to a solid support, e.g., for tethering a monomer, oligomer or polymer to a solid support, which are stable to a wide range of reaction conditions, but can be cleaved under well-defined conditions, thereby liberating the molecule from the solid support. Preferably, the linkers are used to tether to the solid support unprotected, partially-protected or fully-protected monosaccharides or oligosaccharides, or unprotected, partially-protected or fully-protected glycoconjugates. The linkers of the present invention may be used to tether to solid supports building blocks useful in the assembly of libraries of other types of small molecules. The present invention also relates to a molecule or plurality of molecules tethered to the solid support via a linker or linkers of the present invention. The present invention also relates to processes for synthesizing molecules, e.g., monomers, oligomers or polymers, on a solid support, wherein a starting material in the synthesis of the molecule, intermediates in the synthesis of the molecule, and the molecule itself are tethered to the solid support during the process via one of the linkers of the present invention. In certain processes of the present invention, the molecule is liberated from the solid support by cleavage of the linker of the present invention.

专利号:US-2005124592-A1
优先权日:2002-01-22
标 题:Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
发明人：KLOOSTERBOER HELENIUS J; BUNDRED NIGEL
摘要:Disclosed is a treatment of estrogen-deficiency related complaints in females that exhibit these complaints while they are on treatment with a drug which prevents the synthesis of endogenous estrogen. Such drugs are, e.g., anti-cancer drugs such as aromatase inhibitors. The invention resides in the use of tibolone, which has an unexpectedly beneficial working in this particular patient group in that it does not stimulate breast, while preventing bone loss and relieving climacteric complaints in a patient group in which this is more difficult than in any other group due to the nature of the concomitant cancer treatment (no circulating estrogen making for a higher severity of the complaints, the lack of effect on the estrogen receptor making for an increased risk associated with estrogenic breast stimulation once estrogen-like compounds are administered.

专利号:US-10266565-B2
优先权日:2011-04-12
标 题 :Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
发明人：BURKE JR TERRENCE R; LIU FA; LEE KYUNG S; PARK JUNG-EUN
权利人:BURKE JR TERRENCE R; LIU FA; LEE KYUNG S; PARK JUNG EUN; THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
摘要:Novel compounds are provided that bind to polo-like kinases through the polo-box domain. In certain embodiments, the novel compounds are PEGylated peptides. The PEGylated peptides in accordance with the invention demonstrate high PBD-binding affinity. In certain embodiments, the PEGylated peptides have also achieved activities in whole cell systems. The invention also provides compounds that bind polo-like kinases through the polo-box domain and possess reduced anionic charge. Further provided are methods of design and/or synthesis of the PEGylated peptides and methods of use thereof. The invention provides methods of use of the compounds and methods of synthesis of the compounds.

专利号:US-12018313-B2
优先权日:2016-12-28
标题:Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles
发明人：EMBREE MALLORY
权利人:NATIVE MICROBIALS INC
摘要:Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles, including dosed microbial ensembles and inoculative microbial ensembles, are disclosed.

专利号:US-6846917-B2
优先权日:2001-01-23
标题:Solid- and solution-phase synthesis of heparin and other glycosaminoglycans
发明人：SEEBERGER PETER H; ORGUEIRA HERNAN; SCHELL PETER
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides the basis for the preparation of combinatorial libraries and parallel libraries of defined glycosaminoglycan oligosaccharides. The defined glycosaminoglycan structures may be used in high-throughput screening experiments to identify carbohydrate sequences that regulate a host of recognition and signal-transduction processes. The determination of specific sequences involved in receptor binding holds great promise for the development of molecular tools which will allow modulation of processes underlying viral entry, angiogenesis, kidney diseases and diseases of the central nervous system. Notably, the present invention enables the automated synthesis of glycosaminoglycans in much the same fashion that peptides and oligonucleotides are currently assembled.